Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) dropped 3.2% due to negative developments in the healthcare sector, including weakness in managed care providers and unfavorable news from other pharmaceutical and biotech companies. The broader market sentiment about rising costs and inadequate pricing for 2025 plans also contributed to the downward pressure on healthcare equities. The market considered the news meaningful, but it may not fundamentally change its perception of the business. Supernus Pharmaceuticals is down 10.9% since the beginning of the year, trading 18.8% below its 52-week high. This could present a buying opportunity for investors.

Read more at StockStory: Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today